EVOLITO-LIMITED
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics, and battery solutions for aerospace applications, announces the appointment of Marc Holme as CTO, as it prepares for future growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821458/en/
Marc Holme, CTO, Evolito (Photo: Business Wire)
Marc Holme joins as CTO to lead the technology development and the future roadmap of the axial-flux e-motor and propulsion product family. He has a 24-year tenure in aviation, most recently at Collins Aerospace where he was Senior Director of Engineering. Holme’s deep technical background has seen him lead multiple aircraft system electrification programs from Airbus A380 to Boeing 787, and many technology acquisition programs.
Commenting on his appointment, Marc Holme, CTO, Evolito said:
“I’m excited to join Evolito to continue the progression towards more sustainable aviation through electrification. The advanced electric motor technology that originated for the automotive market is being adapted and improved by Evolito to enable aerospace applications where weight, efficiency and safety are critical. Combined with its leading motor control electronics and battery technologies, Evolito is well positioned to reach scalable and sustainable electric aviation.”
The new C-suite hire follows a phenomenal year for the company, having received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products in December 2023. Evolito is already working with a number of OEM partners, developing motors and propulsion systems for a variety of eVTOL, Urban Air Mobility and fixed-wing applications, and expects a series of customer test flights later this year.
Dr. Chris Harris, Evolito CEO and co-founder said:
“The whole company is delighted to welcome Marc to the growing Evolito family. I’m extremely proud of what we have created here at Evolito, and our success is a reflection of our hugely talented and dedicated team, driven by a common passion for sustainable mobility. The electrification of flight is one of the most exciting market opportunities of our time, and Evolito’s innovative new technology and ability to scale means we are well positioned to meet this fast-emerging demand.”
Founded in July 2021, Evolito has grown its experienced team from 15 to over 200. It was recently awarded 2nd place in four award categories in the 2023 Best Companies100 Best Place To Work. In July 2022, Evolito acquired and later integrated Electroflight batteries into the business to offer complete propulsion solutions that are fully optimised for future aircraft applications. Amongst other partners, it works with Cranfield Aerospace Solutions who provide motor and inverters for its hydrogen aircraft demonstrator - the Fresson project.
EDITOR’S NOTES
Evolito
Evolito is making all-electric flight a reality by offering world-leading electric axial flux motors, motor control units and battery systems for the aerospace market. Evolito’s electric propulsion systems offer the highest power, torque, and energy densities in class and are inherently more robust than alternative technologies – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications. The privately-held company is based in Oxford. Evolito’s investors include B-Flexion and Oxford Science Enterprises (OSE).
Marc Holme, CTO, Evolito boasts 24 years of experience in aviation and a further 5 in automotive. Prior to joining Evolito, Holme was Senior Director Engineering at Collins Aerospace. He has also worked for UTC Aerospace Systems and Goodrich. Holme has a masters in power electronics and drives from The University of Birmingham.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416821458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
